The Iverson Genetic Diagnostics company has committed intellectual and financial resources as collaborators for the phase 1 clinical trial.
Lipid Genomics is currently seeking other strategic partners to advance approval
of this investigational new drug from the present early phase clinical trials through to final FDA marketing approval.
We are also interested in advancing the LAG3 diagnostic and LAG3 biologic by partnering with investors interested in different and varied funding mechanisms.
